Patents by Inventor Bee Hui Liu

Bee Hui Liu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • N-(2-Aminophenyl)-Prop-2-Enamide Derivatives, and Uses Thereof in the Treatment of Cancer
    Publication number: 20230202980
    Abstract: Provided herein are N-(2-aminophenyl)-prop-2-enamide derivatives, such as those of Formula (I), methods for the synthesis thereof, and uses thereof in the treatment of cancer, such as SALL4-expressing cancer, in a cell or subject in need thereof.
    Type: Application
    Filed: August 28, 2020
    Publication date: June 29, 2023
    Inventors: Sridhar Radhakrishnan, Daniel G. Tenen, Bee Hui Liu, Kim Anh Vu Le, Mei Lin Go, Li Chai, Chong Gao, Ahmed Kamal, Satish Sunkari, Venkata Subbarao Ayinampudi, Riyaz Syed, Miao Liu
  • Therapeutic spalt-like transcription factor 4 (SALL4) peptide
    Patent number: 10793601
    Abstract: Isolated peptides and pharmaceutical compositions comprising isolated peptides that bind to retinoblastoma binding protein 4 (RBBp4) and block the Spalt-Like Transcription Factor 4 (SALL4)-RBBp4 interaction are described. Methods of inhibiting binding of SALL4 to RBBp4 and methods of treating a subject having a disorder mediated by a dysregulation of SALL4 are also described.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: October 6, 2020
    Assignees: National University of Singapore, The Brigham and Women's Hospital, Inc., Agency for Science, Technology and Research
    Inventors: Bee Hui Liu, Daniel Geoffrey Tenen, Li Chai, Cheng San Brian Chia, Anders Poulsen
  • Therapeutic SALL4 Peptide
    Publication number: 20190218253
    Abstract: The present invention provides, in certain embodiments, isolated peptides and pharmaceutical compositions comprising isolated peptides that bind to retinoblastoma binding protein 4 RBBp4 such that, the binding blocks the SALL4-RBBp4 interaction. Methods of inhibiting binding of SALL4 with RBBp4 and methods for treating a subject having a disorder mediated by a dysregulation of SALL4 are also provided.
    Type: Application
    Filed: April 28, 2017
    Publication date: July 18, 2019
    Inventors: Bee Hui Liu, Daniel Geoffrey Tenen, Li Chai, Cheng San Brian Chia, Anders Poulsen
  • Spalt-like transcription factor 4 (SALL4) and uses thereof
    Patent number: 9365851
    Abstract: Described are methods of treating a solid tumor which expresses Spalt-Like Transcription Factor 4 (SALL4) and Phosphatase and Tensin Homolog (PTEN) in an individual in need thereof, comprising administering to the individual an effective amount of a composition that inhibits SALL4. In addition, the invention is directed to methods of detecting an aggressive cancer in an individual in need thereof as well as methods of detecting a poor prognosis of a patient with cancer in an individual in need thereof.
    Type: Grant
    Filed: September 20, 2012
    Date of Patent: June 14, 2016
    Assignees: National University of Singapore, Brigham and Women's Hospital
    Inventors: Li Chai, Todor Dimitrov, Daniel Geoffrey Tenen, Kol Jia Yong, Bee Hui Liu